A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression
Open accessThe DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
Background Ketamine has rapid-acting antidepressant effects but is associated with psychotomimetic and other adverse effects. A 7-chlorokynurenic acid is a potent and specific glycine site N-methyl-d-aspartate receptor antagonist but crosses the blood-brain barrier inefficiently. Its prodrug, L-4-chlorokynurenine (4-Cl-KYN), exerts acute and sustained antidepressant-like effects in rodents and has no reported psychotomimetic effects in either rodents or healthy volunteers. This study examined whether 4-Cl-KYN has rapid antidepressant effects in individuals with treatment-resistant depression. Methods After a 2-week drug-free period, 19 participants with treatment-resistant depression were randomized to receive daily oral doses of 4-Cl-KYN monotherapy (1080 mg/d for 7 days, then 1440 mg/d for 7 days) or placebo for 14 days in a randomized, placebo-controlled, double-blind, crossover manner. The primary outcome measure was the Hamilton Depression Rating Scale score, assessed at several time points over a 2-week period; secondary outcome measures included additional rating scale scores. Pharmacokinetic measures of 7-chlorokynurenic acid and 4-Cl-KYN and pharmacodynamic assessments were obtained longitudinally and included 1H-magnetic resonance spectroscopy brain glutamate levels, resting-state functional magnetic resonance imaging, and plasma and cerebrospinal fluid measures of kynurenine metabolites and neurotrophic factors. Results Linear mixed models detected no treatment eff…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An additional small (n = 19) phase II crossover of AV-101 in individuals with TRD was also negative (p = 0.71, d = 0.22) [160].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [160]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Development and validation of brief measures of positive and negative affect: The PANAS scales.
Watson, D., Clark, L. A., & Tellegen, A. (1988) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.54.6.1063 · Cited by 32,433
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationAssessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
Research works printed but not linked: 1
- Food and Drug Administration, 1997, Guidance document: dissolution testing of immediate release solid oral dosage forms (No. 97D-0331)
Cited by
Tryptophan Metabolism as a Pharmacological Target
Modoux, M., Rolhion, N., Mani, S., & Sokol, H. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.006 · Cited by 284
The role of dissociation in ketamine’s antidepressant effects
Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 220
Self-citationMuneer, A. (2020) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2020.18.4.507 · Cited by 159
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
“However, a recent phase II, double-blind, 2-week, placebo-controlled, crossover study of 19 participants with TRD found that AV-101 monotherapy (either 1080 mg/day or 1440 mg/day) did not improve participants’ overall depressive symptoms (as assessed by HAM-D total score) [109].”
BackgroundSelf-citationAiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications
Lucido, M. J., Bekhbat, M., Goldsmith, D. R., Treadway, M. T., Haroon, E., Felger, J. C., & Miller, A. H. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000043 · Cited by 137
Zanos, P., Brown, K. A., Georgiou, P., Yuan, P., Zarate, C. A., Thompson, S. M., & Gould, T. D. (2023) · The Journal of Neuroscience · doi:10.1523/jneurosci.1316-22.2022 · Cited by 115
Self-citationBartoli, F., Misiak, B., Callovini, T., Cavaleri, D., Cioni, R. M., Crocamo, C., Savitz, J. B., & Carrà, G. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00913-1 · Cited by 112
The Kynurenine Pathway in Traumatic Brain Injury: Implications for Psychiatric Outcomes
Meier, T. B., & Savitz, J. B. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.05.021 · Cited by 83
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression
Wang, Y., Wang, X., Feng, S., Chen, N., Wang, Z., & Zhang, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105761 · Cited by 69
Kadriu, B., Musazzi, L., Johnston, J. N., Kalynchuk, L. E., Caruncho, H. J., Popoli, M., & Zarate, C. A. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.027 · Cited by 62
Self-citationLv, S., Yao, K., Zhang, Y., & Zhu, S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109378 · Cited by 61
The Function of the Kynurenine Pathway in the Placenta: A Novel Pharmacotherapeutic Target?
Broekhuizen, M., Danser, A. H. J., Reiss, I. K. M., & Merkus, D. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111545 · Cited by 57
LAT1, a novel pharmacological target for the treatment of glioblastoma
Cappoli, N., Jenkinson, M. D., Russo, C. D., & Dickens, D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115103 · Cited by 50
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Brown, K. A., & Gould, T. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02397-1 · Cited by 49
Self-citationPharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“An additional small ( n = 19) phase II crossover of AV-101 in individuals with TRD was also negative ( p = 0.71, d = 0.22) [160].”
BackgroundInfluentialSelf-citationBrown, S. J., Christofides, K., Weissleder, C., Huang, X.-F., Shannon Weickert, C., Lim, C. K., & Newell, K. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01736-8 · Cited by 44
Alves, L. D. F., Moore, J. B., & Kell, D. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169082 · Cited by 43
Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design
Tanaka, M., Szatmári, I., & Vécsei, L. (2025) · Pharmaceuticals · doi:10.3390/ph18050607 · Cited by 29
Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease
Luca, D. G. D., Reyes, N. G. D., & Fox, S. H. (2022) · Drugs · doi:10.1007/s40265-022-01747-7 · Cited by 43
Clinical specificity profile for novel rapid acting antidepressant drugs
Scala, M., Fanelli, G., De Ronchi, D., Serretti, A., & Fabbri, C. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000488 · Cited by 41
Progress in the development of kynurenine and quinoline-3-carboxamide-derived drugs
Boros, F. A., & Vécsei, L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1813716 · Cited by 39
Targeting NMDA Receptors in Emotional Disorders: Their Role in Neuroprotection
Wang, S., Bian, L.-H., Yin, Y., & Guo, J. (2022) · Brain Sciences · doi:10.3390/brainsci12101329 · Cited by 38
Chaki, S., & Watanabe, M. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109348 · Cited by 30
Quinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design
Tanaka, M., Szatmári, I., & Vécsei, L. (2025) · doi:10.20944/preprints202503.2399.v1 · Cited by 30
Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864902 · Cited by 29
“(169) 12, 0 (1)H-MRS and fMRI pgACC 30 ROIs previously identified as being associated with MDD using a 6mm sphere Pre-treatment and ∼60–120min post-treatment”
MethodMurphy, N., Ramakrishnan, N., Vo-Le, B., Vo‐Le, B., Smith, M. A., Iqbal, T., Swann, A. C., Mathew, S. J., & Lijffijt, M. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00917-z · Cited by 26
Self-citationVasiliu, O. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884155 · Cited by 22
Saez, E., Erkoreka, L., Moreno-Calle, T., Berjano, B., González-Pinto, A. M., Basterreche, N., & Arrúe, A. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i7.884 · Cited by 22
Involvement of Kynurenine Metabolism in Bipolar Disorder: An Updated Review
Zhang, P., Huang, H., Gao, X., Jiang, J., Xi, C., Wu, L., Fu, Y., Lai, J., & Hu, S. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.677039 · Cited by 21
Pilc, A., Machaczka, A., Kawalec, P., Smith, J. L., & Witkin, J. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2111415 · Cited by 21
Hecking, J., Davoudian, P. A., & Wilkinson, S. T. (2021) · Chronic Stress · doi:10.1177/24705470211020446 · Cited by 20
Neuroimmunometabolism: how metabolism orchestrates immune response in healthy and diseased brain
Rana, A. K., Bhatt, B., Gusain, C., Biswal, S., Das, D., & Kumar, M. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00331.2024 · Cited by 18
Patel, W., Rimmer, L. J., Smith, M., Moss, L., Smith, M. A., Snodgrass, H. R., Pirmohamed, M., Alfirevic, A., & Dickens, D. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00727 · Cited by 18
Self-citationNot So Fast: Recent Successes and Failures in Treating Depression
Kadriu, B., Deng, Z., Kraus, C., Henter, I. D., Lisanby, S. H., & Zarate, C. A. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19ac13138 · Cited by 16
Self-citationBourque, M., Grégoire, L., Patel, W., Dickens, D., Snodgrass, R., & Paolo, T. D. (2022) · Cells · doi:10.3390/cells11223530 · Cited by 16
Jiang, Y., Dong, Y., & Hu, H. (2024) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2023.0225 · Cited by 15
Advancing past ketamine: emerging glutamatergic compounds for the treatment of depression
Freudenberg, F., Reif-Leonhard, C., & Reif, A. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01875-z · Cited by 15
Targeting the dysfunction of glutamate receptors for the development of novel antidepressants
Xia, C., He, J., Du, L., Yan, Y., Lian, W., Xu, J., & Zhang, W. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107875 · Cited by 15
The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine
Park, D., Lee, G., Lee, W.-G., Kim, B. S., Lee, Y., & Kim, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03100-2 · Cited by 14
Tanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Kojic, M., Saelens, J., Kadriu, B., Zarate, C. A., & Kraus, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_313 · Cited by 13
Self-citationDong, Z., Grunebaum, M. F., Lan, M. J., Wagner, V., Choo, T.-H. J., Milak, M. S., Sobeih, T. M., Mann, J. J., & Kantrowitz, J. T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.653026 · Cited by 13
Role of group II metabotropic glutamate receptors in ketamine's antidepressant actions
Onisiforou, A., Georgiou, P., & Zanos, P. (2023) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2023.173531 · Cited by 12
Self-citationExperimental Therapeutics in Treatment-Resistant Major Depressive Disorder
Kaur, M., & Sanches, M. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s259302 · Cited by 12
Eggertsen, P. P., Palmfeldt, J., Pedersen, A. R., Frederiksen, O.-V., Olsen, R. K. J., & Nielsen, J. F. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123016 · Cited by 11
Crossing the Borders: the amino acid transporter LAT1 (SLC7A5) in the Blood-Brain Barrier
Scalise, M., Scanga, R., Console, L., Galluccio, M., Marzano, F., Magrì, A., Pochini, L., & Indiveri, C. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.106070 · Cited by 10
Shamabadi, A., Ahmadzade, A., Aqamolaei, A., Mortazavi, S. H., Hasanzadeh, A., & Akhondzadeh, S. (2022) · Iranian Journal of Psychiatry · doi:10.18502/ijps.v17i3.9733 · Cited by 10
New advances in small molecule drugs targeting NMDA receptors
Zeng, Y., Qu, Z.-Y., Zhu, Q., Wang, H., Zhou, Y., & Gao, Z.-B. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01675-8 · Cited by 9
Role of Transporters and Enzymes in Metabolism and Distribution of 4-Chlorokynurenine (AV-101)
Patel, W., Shankar, R. G., Smith, M. A., Snodgrass, H. R., Pirmohamed, M., Jorgensen, A., Alfirevic, A., & Dickens, D. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00700 · Cited by 9
Self-citationWang, K., DiChiacchio, T., Fang, W. L., Lander, L. R., Feinberg, J., Xie, C., Winstanley, E. L., & Piamjariyakul, U. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.10.018 · Cited by 9
Balog, E., Jenei, G., Berkó, A. M., Lőrinczi, B., Szatmári, I., Vécsei, L., Toldi, J., & Kis, Z. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138220 · Cited by 7
Targeting NMDA receptor signaling for therapeutic intervention in brain disorders
Chen, H., Dong, Y., Wu, Y. J., & Yi, F. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0096 · Cited by 7
Anhedonia in Depressive Disorder and Schizophrenia: An Overview of Causes, Diagnosis, and Treatment
Pelc, M. L., Białek, A. B., Stasiewicz, O. A., Sobecka, N. O., & Soroka, E. (2025) · Medical Science Monitor · doi:10.12659/msm.950368 · Cited by 5
Neural Receptors Associated with Depression: A Systematic Review of the Past 10 Years
Câmara, A. B., & Brandão, I. A. (2020) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527319666200715102430 · Cited by 5
Exploring New Frontiers in Pharmacological Treatment of Depression: A Review on Recent Advances
Thulasingam, M., & Vellapandian, C. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673342524250109181220 · Cited by 3
Metabolic dysfunction contributes to mood disorders after traumatic brain injury
Liu, L., Jia, P., Liu, T., Liang, J., Dang, Y., Rastegar‐Kashkooli, Y., Li, Q., Liu, J., Man, J., Zhao, T., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102652 · Cited by 3
Research Progress of Tryptophan and Its Metabolites in the Microbial-Gut-Brain Axis
唐, 婕. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1461901 · Cited by 2
Walpole, S. J., & Newell, K. A. (2024) · Science Progress · doi:10.1177/00368504241274494 · Cited by 2
Perspective Chapter: NMDA Treatments for CNS Disorders
Lin, C.-H., Shih, P., & Tsai, G. E. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100528
Sage 217 (Zuranolone) for Treatment of Major Depressive Disorder
Beresis, R. T. (2022) · Wiley eBooks · doi:10.1002/9781119847281.ch14
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders
Куркин, Д. В., Morkovin, E. I., Bakulin, D. A., Gorbunova, Y. V., Ivanova, O. V., Pavlova, E. V., Зверева, В. И., Dzhavakhyan, M. A., Сергеевич, К. И., Kolosov, Y. A., et al. (2024) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202412405122
Chapter 22. Ketamine and Other Investigational Agents
(2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615379620.lg22
Brugger, F., & Hägele-Link, S. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108989855.026
The kynurenine pathway in major depressive disorder
Brown, S. J. (2023) · Research Online (University of Wollongong)
Discovery of the 5-Chlorokynurenine Pathway in Lodopyridone Biosynthesis
Avila, M. J., Lan, T., & Moore, B. S. (2026) · Journal of Natural Products · doi:10.1021/acs.jnatprod.6c00490
Le, G. H., Wong, S., Selby, S., & McIntyre, R. S. (2026) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2026.105178
Li, Y., Li, J., Zhao, Z., Tang, Y., Li, Z., Wang, C., Zhang, T., Luo, A., & Hao, Z. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18111428
Metadata
- Authors
- Park, L. T., Kadriu, B., Gould, T. D., Zanos, P., Greenstein, D., Evans, J. W., Yuan, P., Farmer, C. A., Oppenheimer, M., George, J. M., Adeojo, L. W., Snodgrass, H. R., Smith, M. A., Henter, I. D., Machado-Vieira, R., Mannes, A. J., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- University of Maryland, Baltimore (US)
- VistaGen Therapeutics (United States) (US)
- Augusta University (US)
- Department of Psychiatry and Behavioral Sciences, McGovern Medical School, University of Texas Science Center, Houston, TX
- Corresponding author
- Park, Lawrence T
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03-31
- Volume
- 23
- Issue
- 7
- Pages
- 417-425
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7387765
- OpenAlex
- W3014355680
- Cited by
- 63
- References
- 47
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 11 · 2023: 6 · 2022: 14 · 2021: 13 · 2020: 9
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (ZIAMH002857, NCT02484456)
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- treatment-resistant depression, 7-chlorokynurenic acid, prodrugs, antidepressant efficacy, psychotomimetic effects, kynurenine metabolites, brain glutamate, neurotrophic factors, drug safety and tolerability
- MeSH terms
- Adolescent, Adult, Aged, Animals, Antidepressive Agents, Brain, Brain Chemistry, Double-Blind Method, Female, Glycine, Humans, Kynurenine, Magnetic Resonance Imaging, Male, Middle Aged, Prodrugs, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Cross-Over Studies, Mice, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.